Avn 2002, the FDA approved Avodart (dutasteride 0.5mg) for the treatment of prostate enlargement in men (the medical term is symptomatic benign prostatic hyperplasia or BPH). Dutasteride is not approved for the treatment of male pattern hair loss.
Generic Avodart which is known as Dutasteride inhibits both type 1 and type 2 5 acts as reductase, ood for the treatment of for BHP or called as Symptomatic Benign Prostatic Hyperplasia which this medicine is already approved on 0.5 mg. This is very potent which is actually thrice as potent as finasteride on inhibiting the type 15 known as the reductase enzyme. This drug medicine was approved in 2002 by FDA for the treatment on prostate enlargement among men or BHP. It is not actually approved for hair loss treatment but still may are experimenting on using it for their hair.
Dutasteride is like finasteride which is an inhibitor of enzyme 5 alphas, the alpha reductase which is in control for the changing of testosterone into DHT or dihydrotestosterone. This unique medicine inhibits not only Type II enzyme but also Type I of 5 alphas. Thus it gives a dual effect to enhance the potency of the drug yet increases the adverse reactions.
Use for BHP treatment.
Dutasteride can be swallow either there’s a food or none. Regular of schedule intake depends on your physician.
Not recommended for patients with hypersensitivity on this drugs and on its ingredients.
Pregnant woman or will become pregnant never use this drug nor handle it. Blood intoxication for men are prone which they are not allowed to donate once they are taking this medicine even after six months. Men who have allergic reactions on this medicine or to its ingredients should never take it. Those men who have liver disease must tell their physician before taking dutasteride due to potential ill effects on drug to drug interactions, so extra care should be done in administering on dutasteride among patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir).
This medicine affects or can attribute to defects of physiological progress from dutasteride is unsafe to male children. The adverse effects would be similar to 5-alpha-reductase deficiency, where a developing male child is naturally deficient in 5-alpha reductase type II, and thus unable to synthesize it. As Dutasteride acts as a barrier for the growth and development of males who have such DHT deficiency as a result of the ill effect of this drug. Men who are having a medication on this drug are prohibited to give in blood donations, which can take 6 months for its long effect in the body of the person. Birth defects are also the result of this drug medication among pregnant women especially when such pregnant woman receive a blood transfusion which hasdutasteride.
Store the medicine in 25°C or 770 F. Keep it away from moisture, heat and light of the sun. Storage room must be 15° to 30°C.